Lineage Cell Therapeutics Inc (AMEX:LCTX)’s traded shares stood at 2.31 million during the last session, with the company’s beta value hitting 1.38. At the close of trading, the stock’s price was $1.29, to imply an increase of 12.17% or $0.14 in intraday trading. The LCTX share’s 52-week high remains $1.61, putting it -24.81% down since that peak but still an impressive 34.88% since price per share fell to its 52-week low of $0.84. The company has a valuation of $243.20M, with an average of 918.56K shares over the past 3 months.

Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information

After registering a 12.17% upside in the last session, Lineage Cell Therapeutics Inc (LCTX) has traded red over the past five days. The stock hit a weekly high of 1.4500, jumping 12.17% in its intraday price action. The 5-day price performance for the stock is -4.44%, and 10.26% over 30 days. With these gigs, the year-to-date price performance is 18.35%.

Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts

Looking at statistics comparing Lineage Cell Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors.

LCTX Dividends

Lineage Cell Therapeutics Inc has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Lineage Cell Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.